Patients with ME/CFS desperately need answers. We are convinced these answers are readily available if we apply the best resources in a large-scale, concerted effort.  Linda Tannenbaum , Executive Director, Open Medicine Foundation

…He Has A Plan

Dr Andreas Kogelnik, the leader behind OMI-MERIT has an MD, a Ph.D in bioengineering and did post-graduate work in immunology, microbiology and bioinformatics.   He worked with Dr. Montoya at Stanford on the ME/CFS antiviral trials but felt that projects could deliver results faster outside of academia so in 2009, he left to create the Open Medicine Institute (OMI).  Back in 1998 he also managed to start a software company called Flexis.


Collaboration and networking are key parts of OMI-MERITS plan

Take a close look at his past;  bioengineering, molecular biology and genomics, microbiology, bioinformatics and software and you have the foundations for OMI-MERIT.   The Open Medicine Institute and OMI-MERIT  is a digitally derived, opensourced, 21st century research effort  that aims to collect, analyze and apply massive amounts of data to solve the unknowns around ME/CFS.

How does the Open Medicine Institute plan to do that? They  innovate, they  collaborate and they  ‘crowdsource’ in every way they can.  Networking, using efficiencies of scale and crowdsourcing is Kogelnik’s forte.  He’s  got ideas sprouting out of his head how to jam immunology, bioinformatics and social networking  together to produce results. (We’ll se e much of this in an interview coming up).  He’s thinking on a vast scale in ME/CFS and neuroimmune disease.

In some ways you have to operate that way to get at chronic fatigue syndrome. It’s a messy disorder that doesn’t lend itself to small solutions.  The research is pretty scanty, the definition relies on symptoms and poor funding and  small research studies have been the norm.  Given that, it’s no surprise we’re still mucking around with the definition problem thirty years later.  Thus far this research field has been like the blind men and the elephant; everyone has their view point and each is partially right but all are missing the big picture.

Building that big picture will take big studies that can  encapsulate the disorder, organize it and then break it down into its constituent parts.  It will take  projects that can capture ME/CFS in all its  glory and then dig down to  uncover the subsets in it.   That is what OMI-MERIT more than any other research effort that I can tell  is about.

It took about 20 ME/CFS luminaries two days in New York City, last year  to figure out  how to do that.  Many of the major figures  (Bateman, Fluge, Mella, Hornig, Klimas, Lapp, Light, (didn’t make it), Montoya, Peterson, etc.) were there but there were also some new additions such as Ron Davis, an eminent geneticist/genomist working out of Stanford, Yenan Bryceson, an immunologist from Sweden and  Simone Pensieroso, a virologist from Italy.

They came up with a $14 million dollar laundry list that they think could do wonders for ME/CFS.

Rituximab Trial

OMI-MERITS first (and most expensive) project – a big rituximab/valganciclovir  trial – is a good example of how OMI-MERIT and Kogelnik works. The first thing to notice is that it’s big – aiming for up to 500 patients  – and in the molecular field bigger is definitely better.

Besides figuring out if rituximab and valganciclovir are effective treatments, the trial would also employ ‘exceptional measures’  of genomic, immunologic, virologic and physiologic markers.  The OMI-MERIT  take would essentially  throw the molecular book and then some, so to speak, at the patients in the trial  to try to  learn what’s going on  in patients  that get better and what isn’t going on  in those that didn’t get better.


A combined Rituximab/antiviral trial is OMI-MERIT’s top priority project. It’s also easily their most expensive one.

Why go to the extra trouble?  Because this is a two-fer trial; this isn’t just about getting better on  Rituximab and Valganciclovir – it’s also about finding biomarkers that finally expose the  subsets  present in this disorder. Detailing the physiologic changes that occur as some patients improve will expose the deficits that allowed them to get ill in the first place. This makes patients that are getting better  a great  place to look for biomarkers.

Beside, while  some patients may recover  many will ‘just’ get better and getting them all the way better will require knowing  exactly what’s gone wrong so that better drugs  or drug combinations can be produced. This trial and the MERIT projects as a whole aren’t about just getting better, they’re about getting at the roots of ME/CFS.

This two or three or four-fer approach is how Kogelnik and the really good researchers in the field work.  There’s always more than you think going on…  as far as rituximab is concerned, this is the way to go.

International Neuro Registry and Biobank

The second priority on OMI-MERIT’s list – the International Neuro-registry  and Biobank –  also exemplifies OMI-MERIT’s conviction that breaking the code on this disorder requires big data. Not only would this registry be huge (10,000 patient samples) and comprehensive (blood, saliva, stool, spinal fluid, etc.) but it would track patients over time.   This combination would allow researchers to get at the ‘biological clusters’ ; ie the subsets in the ME/CFS population.   This is already off to a great start through the OMI Clinical Research Network and will open for general public input later this year.

Other Projects

Other projects would look at protein panels to identify viral, bacterial, antibody, hormonal, cytokine and other protein based substances in patients substances. Another project would take a cut at treatment, this time looking at drugs such as Famvir, Ampligen, Etanercept, Rifaxamin, Issentris and others, all the while pinpointing molecular changes  to identify biomarkers. A particularly exciting immunologic project would examine B, T, NK  cells responses using  methods never before applied  to patients in this disorder.

Lab tests

OMI-MERIT is committed to building an enormous neuro-immune repository for ME/CFS

Worried about toxins? One project will use mass spectroscopy to identify toxins and unknown compounds to find unusual substances that could be mucking up ME/CFS patients systems.  Have problems with pathogens? A pathogen project would identify a core group of testing methodologies for the pathogens in ME/CFS.  With disagreement about how to test for many pathogens, any study that established standardized procedures would be a substantial advance.

Genetics?  Another project will run several whole genomes as well as up to 1000 HLA gene sequences and DNA methylation.    Hypervariable parts of our DNA focused on immune functioning the HLA sequence study could hold gold for ME/CFS patients.  Amongst the most  difficult parts of the genome to characterize, OMI-Merit’s focus this area speaks to the expertise they’ve been able to bear in the research.


Bringing together the right experts and the most advanced technologies to deliver actionable results is a necessary condition for success that has been a long time coming to this field. – Linda Tannenbaum , Executive Director, Open Medicine Foundation

Is OMI-MERIT revoluitionary? In its scope and vision it is. We recently heard Bernard Munos, a biopharma insider call at the FDA Stakeholder’s meeting state that  ‘big data’, collaboration and an open source approach to the this disorder will bring industry to the table.. By bringing ME/CFS experts together to set out an agenda and build an open-sourced platform OMI- Merit is doing just that. With the CFIDS Association bringing its commitment to open source and  soon its tools to foster that we have two major players hopefully setting the stage for a new era of research.

Health Rising Exists Because of Your Support



A BIG thanks to the 320 people who helped make Health Rising's fundraising drive a success!

Stay Up to Date with ME/CFS, Long COVID and Fibromyalgia News

Get Health Rising's free blogs featuring the latest findings and treatment options for the ME/CFS, long COVID, fibromyalgia and complex chronic disease communities. 

Thanks for subscribing! :)

Pin It on Pinterest

Share This